{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T09:28:16Z","timestamp":1773221296961,"version":"3.50.1"},"reference-count":13,"publisher":"The Journal of Rheumatology","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Rheumatol"],"published-print":{"date-parts":[[2012,4]]},"abstract":"Objective.<\/jats:title>To describe the clinical characteristics of patients referred for gold therapy and determine the reason for referral.<\/jats:p><\/jats:sec>Methods.<\/jats:title>We conducted a chart review of patients referred for gold at the Mary Pack Arthritis Program, Vancouver, Canada, from July 2007 to July 2009.<\/jats:p><\/jats:sec>Results.<\/jats:title>The sample included 69 female and 12 male patients. Diagnosis was rheumatoid arthritis (RA) in 71\/81, psoriatic arthritis in 5, juvenile idiopathic arthritis (JIA) in 2, Sj\u00f6gren syndrome in 1, undifferentiated polyarthritis in 1, and spondyloarthritis in 1. Twenty of 81 patients had received gold before: 15 were referred for a second course, 4 a third course, and 1 a fourth course. Ten of 81 patients were referred for gold as their first disease-modifying antirheumatic drug (DMARD). Seventy-one had received prior DMARD: 1 prior DMARD in 22 patients, 2 in 24 patients, 3 in 15 patients, and > 3 in 6 patients. Four patients had received prior biologic therapy plus 2 to 4 prior DMARD. Twelve of 71 received gold monotherapy, 56\/71 received gold\/DMARD combinations, and 3 received gold\/biologic\/DMARD combinations. Reasons for referral included failure of other DMARD in 54 patients, limited DMARD options in 50 (chronic liver disease in 34, sulfa allergy in 7, high alcohol consumption in 5, and planning pregnancy in 4), physician choice in 12, previous benefit from gold in 10, benefit of clinic support in 10, inappropriate for biologics in 7, patient choice in 4, and failure of biologics in 3.<\/jats:p><\/jats:sec>Conclusion.<\/jats:title>The most common reasons for referral to gold clinic in 2007 to 2009 are failure of other DMARD and limited DMARD options due to underlying liver disease.<\/jats:p><\/jats:sec>","DOI":"10.3899\/jrheum.111097","type":"journal-article","created":{"date-parts":[[2012,2,16]],"date-time":"2012-02-16T06:55:28Z","timestamp":1329375328000},"page":"716-719","source":"Crossref","is-referenced-by-count":4,"title":["Characterization of Patients with Arthritis Referred for Gold Therapy in the Era of Biologics"],"prefix":"10.3899","volume":"39","author":[{"given":"JESSICA M.","family":"CHEUNG","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"DEBRA","family":"SCARSBROOK","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"ALICE V.","family":"KLINKHOFF","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2262","published-online":{"date-parts":[[2012,2,15]]},"reference":[{"key":"2018112909274297000_39.4.716.1","doi-asserted-by":"publisher","DOI":"10.1007\/s00011-003-1208-2"},{"key":"2018112909274297000_39.4.716.2","doi-asserted-by":"publisher","DOI":"10.1097\/00045391-200103000-00007"},{"key":"2018112909274297000_39.4.716.3","first-page":"127","article-title":"Pharmacology of gold compounds in rheumatoid arthritis: A review","volume":"4","author":"Noriega","year":"1997","journal-title":"Can J Clin Pharmacol"},{"key":"2018112909274297000_39.4.716.4","doi-asserted-by":"publisher","DOI":"10.1002\/art.21018"},{"key":"2018112909274297000_39.4.716.5","unstructured":"Gordon DA Klinkhoff AV . Second line agents. In: Harris ED Budd MD Genovese MC Firestein GS Sergent JS Ruddy S Sledge CB , editors. Kelley\u2019s textbook of rheumatology. 7th ed. Chapter 58. Philadelphia: Elsevier Saunders; 2005:886\u201393."},{"key":"2018112909274297000_39.4.716.6","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.1002\/art.27409","article-title":"Aurothiomalate inhibits cyclooxygenase 2, matrix metalloproteinase 3, and interleukin-6 expression in chondrocytes by increasing MAPK phosphatase 1 expression and decreasing p38 phosphorylation","volume":"62","author":"Nieminen","year":"2010","journal-title":"Arthritis Rheum"},{"key":"2018112909274297000_39.4.716.7","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2005.044354"},{"key":"2018112909274297000_39.4.716.8","doi-asserted-by":"publisher","DOI":"10.1002\/art.23721"},{"key":"2018112909274297000_39.4.716.9","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2009.126532"},{"key":"2018112909274297000_39.4.716.10","first-page":"255","article-title":"Prescribing trends in disease modifying antirheumatic drugs for rheumatoid arthritis: A survey of practicing Canadian rheumatologists","volume":"29","author":"Pope","year":"2002","journal-title":"J Rheumatol"},{"key":"2018112909274297000_39.4.716.11","first-page":"2331","article-title":"How Canadian and US rheumatologists treat moderate or aggressive rheumatoid arthritis: A survey","volume":"25","author":"Maetzel","year":"1998","journal-title":"J Rheumatol"},{"key":"2018112909274297000_39.4.716.12","first-page":"1827","article-title":"Gold therapy in women planning pregnancy: Outcomes in one center","volume":"34","author":"Almarzouqi","year":"2007","journal-title":"J Rheumatol"},{"key":"2018112909274297000_39.4.716.13","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1056\/NEJM198008073030602","article-title":"HLA-DR antigens and toxic reaction to sodium aurothiomalate and D-penicillamine in patients with rheumatoid arthritis","volume":"303","author":"Wooley","year":"1980","journal-title":"N Engl J Med"}],"container-title":["The Journal of Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.3899\/jrheum.111097","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,11,29]],"date-time":"2018-11-29T18:10:21Z","timestamp":1543515021000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.jrheum.org\/lookup\/doi\/10.3899\/jrheum.111097"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,2,15]]},"references-count":13,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2012,4,1]]},"published-print":{"date-parts":[[2012,4]]}},"alternative-id":["10.3899\/jrheum.111097"],"URL":"https:\/\/doi.org\/10.3899\/jrheum.111097","relation":{},"ISSN":["0315-162X","1499-2752"],"issn-type":[{"value":"0315-162X","type":"print"},{"value":"1499-2752","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,2,15]]}}}